









Markets
/
Stocks
/
nasdaq-tcrt
/

Alaunos Therapeutics Inc

TCRT



View Detailed Chart

3.560USD

-0.420-10.55%

Close 12/19, 16:00（ET）Quotes delayed by 15 min

7.85MMarket Cap

LossP/E TTM



Alaunos Therapeutics Inc

3.560

-0.420-10.55%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

-10.55%

5 Days

-16.43%

1 Month

+0.28%

6 Months

-17.02%

Year to Date

+86.88%

1 Year

+81.63%

View Detailed Chart

TradingKey Stock Score of Alaunos Therapeutics Inc

Currency: USD Updated: 2025-12-19

Key Insights

Alaunos Therapeutics Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 229/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend up.Despite a good stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Alaunos Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

229 / 404

Overall Ranking

483 / 4582

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

0.000

Target Price

0.00%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Alaunos Therapeutics Inc Highlights

StrengthsRisks

Alaunos Therapeutics, Inc. is a pre-clinical obesity and metabolic disorder and clinical-stage oncology-focused cell therapy company. The Company focuses on developing small molecules that are expected to be efficacious against obesity and other metabolic disorders. The Company is engaged in developing novel small molecule-based obesity therapeutics. The Company’s operations consist primarily of conducting research and development and raising capital to fund those efforts. The Company has not generated any revenues.

Growing

The company is in a growing phase, with the latest annual income totaling USD 10.00K.

Undervalued

The company’s latest PE is -1.57, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 104.76K shares, decreasing 59.27% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 23.00 shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of -0.64.